IGC Pharma (IGC) Q2 2026 earnings summary

Executive summary

• Lead drug candidate IGC-AD1 reached target enrollment of 146 patients in the Phase 2 CALMA trial for agitation in Alzheimer's dementia; trial is within six randomizations of enrollment closure and remains ongoing with follow-up activities.

• Topline data from the CALMA trial is expected in Q4 2026 after patient follow-up, database lock, and unblinding.

• Pipeline includes early-stage candidates (e.g., TGR-63) and proprietary AI platforms (MINT-AD, AHA) for Alzheimer's research and clinical support.

• Revenue primarily from life sciences segment, with focus shifting to clinical development and AI platform advancement.

• IGC-AD1 targets agitation in Alzheimer's dementia, addressing a significant unmet need.

Financial highlights

• Q2 2026 revenue was $265K, down 19% year-over-year; six-month revenue was $582K, down 12%.

• Net loss for Q2 2026 was $3.0M ($0.03/share), compared to $1.6M ($0.02/share) in the prior-year quarter; six-month net loss was $5.34M (vs. $2.80M prior year).

• Gross margin declined to 18% from 47% year-over-year due to product mix and transition to third-party manufacturing.

• Cash and cash equivalents at June 30, 2026, were $331K, down from $900K at year-end 2025.

• R&D expenses increased to $1.4M from $851K year-over-year, reflecting CALMA investment.

Outlook and guidance

• Management expects continued operating losses as clinical and research programs advance.

• Existing cash, anticipated financing, and a $12M credit facility are expected to support operations for at least 12 months, subject to renewal and market conditions.

• CALMA topline readout anticipated in Q4 2026, with ongoing focus on data quality and regulatory readiness.

• Focus remains on completing CALMA trial, advancing AI platforms, and seeking non-dilutive grants.